medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2015, Número 2

<< Anterior Siguiente >>

Ann Hepatol 2015; 14 (2)


Usefulness of serum thyroid-stimulation hormone (TSH) as a prognostic indicator for acute-on-chronic liver failure

Wu Y, You S, Zang H, Liu H, Mao Y, Mao P, Zhu B, Xu J, Xie G, Guo J, Li D, Xin S, Wan Z

Idioma: Ingles.
Referencias bibliográficas: 37
Paginas: 218-224
Archivo PDF: 123.52 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Antonelli A, Ferri C, Pampana A, Fallahi P, Nesti C, Pasquini M, Marchi S, et al. Thyroid disorders in chronic hepatitis C. Am J Med 2004; 117: 10-3.

  2. Antonelli A, Ferri C, Fallahi P, Ferrari SM, Ghinoi A, Rotondi M, Ferrannini E. Thyroid disorders in chronic hepatitis C virus infection. Thyroid 2006; 16: 563-72.

  3. Borzio M, Caldara R, Borzio F, Piepoli V, Rampini P, Ferrari C. Thyroid function tests in chronic liver disease: evidence for multiple abnormalities despite clinical euthyroidism. Gut 1983; 24: 631-6.

  4. Oren R, Sikuler E, Wong F, Blendis LM, Halpern Z. The effects of hypothyroidism on liver status of cirrhotic patients. J Clin Gastroenterol 2000; 31: 162-3.

  5. Silveira MG, Mendes FD, Diehl NN, Enders FT, Lindor KD. Thyroid dysfunction in primary biliary cirrhosis, primary sclerosing cholangitis and non-alcoholic fatty liver disease. Liver Int 2009; 29: 1094-100.

  6. Carulli L, Ballestri S, Lonardo A, Lami F, Violi E, Losi L, Bonilauri L, et al. Is nonalcoholic steatohepatitis associated with a high-though-normal thyroid stimulating hormone level and lower cholesterol levels? Intern Emerg Med 2013; 8: 297-305.

  7. Sarin SK, Kumar A, Almeida JA, Chawla YK, Fan ST, Garg H, de Silva HJ, et al. Acute-on-chronic liver failure; consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). Hepatol Int 2009; 3: 269-82.

  8. Ke WM, Ye YN, Huang S. Discriminate function for prognostic indexes and probability of death in chronic severe hepatitis B. J Gastroenterol 2003; 38: 861-4.

  9. You SL, Rong YH, Zhu B, Zhang AM, Zang H, Liu HL, Dongze L, et al. Changing etiology of liver failure in 3,916 patients from northern China: a 10-year survey. Hepatol Int 2013; 7: 714-20.

  10. Baruch Y, Assy N, Amit T, Krivoy N, Strickovsky D, Orr ZS, Hochberg Z. Spontaneous pulsatility and pharmacokinetics of growth hormone in liver cirrhotic patients. J Hepatol 1998; 29: 559-64.

  11. Caregaro L, Alberino F, Amodio P, Merkel C, Angeli P, Plebani M, Angelo Gatta. Nutritional and prognostic significance of serum hypothyroxinemia in hospitalized patients with liver cirrhosis. J Hepatol 1998; 28: 115-21.

  12. Kabadi UM, Premachandra BN. Serum T3 and reverse T3 levels in hepatic cirrhosis: relation to hepatocellular damage and normalization on improvement in liver dysfunction. Am J Gastroenterol 1983; 78: 750-5.

  13. Huang YH, Tsai MM, Lin KH. Thyroid hormone dependent regulation of target genes and their physiological significance. Chang Gung Med J 2008; 31: 325-34.

  14. Pilo A, Iervasi G, Vitek F, Ferdeghini M, Cazzuola F, Bianchi R. Thyroidal and peripheral production of 3,5,3’-triiodothyronine in humans by multicompartmental analysis. Am J Physiol 1990; 258: E715-E726.

  15. Mansour-Ghanaei F, Mehrdad M, Mortazavi S, Joukar F, Khak M, Atrkar-Roushan Z. Decreased serum total T3 level in hepatitis B and C related cirrhosis by severity of liver damage. Ann Hepatol 2012; 11: 667-71.

  16. Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Diseases and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Diagnostic and treatment guidelines for liver ailure. ZhonghuaGanZang Bing ZaZhi 2006; 14: 643-6.

  17. Chinese Society of Infectious Diseases and Parasitology; Chinese Society of Hepatology. Management scheme of diagnostic and therapeutic criteria of viral hepatitis. Zhonghua Gan Zang Bing ZaZhi 2000; 8: 324-9.

  18. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberq CL, D’Amico G, et al. model to predict survival in patients with end-stage liver disease. Hepatol 2001; 33: 464-70.

  19. Chopra IJ, Teco GN, Mead JF, Huang TS, Beredo A, Solomon DH. Relationship between serum ree fatty acids and thyroid hormone binding inhibitor in nonthyroid illnesses. J Clin Endocrinol Metab 1985; 60: 980-4.

  20. Zietz B, Lock G, Plach B, Drobnik W, Grossmann J, Scholmerich J, Straub RH. Dysfunction of the hypothalamic-pituitary-glandular axes and relation to Child-Pugh classification in male patients with alcoholic and virus-related cirrhosis. Eur J Gastroenterol Hepatol 2003;

  21. Tilg H, Wilmer A, Vogel W, Herold M, Nolchen B, Judmaier G, Huber C. Serum levels of ytokines in chronic liver diseases. Gastroenterol 1992; 103: 264-74.

  22. Jones TH, Kennedy RL. Cytokines and hypothalamic-pituitary function. Cytokine 1993; 5: 31-8.

  23. del Rey A, Furukawa H, Monge-Arditi G, Kabiersch A, Voigt KH, Besedovsky HO. Alterations n the pituitary-adrenal axis of adult mice following neonatal exposure to interleukin- 1. rain Behav Immun 1996; 10: 235-48.

  24. Wiest R, Das S, Cadelina G, Garcia-Tsao G, Milstien S, Groszmann RJ. Bacterial ranslocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J Clin Invest 1999; 104: 1223-33.

  25. Vogeser M, Fischer G, Jacob K. Quantification of cortisol inactivation in cirrhosis of he liver. Exp Clin Endocrinol Diabetes 1998; 106: 410-4.

  26. Tatar E, Kircelli F, Asci G, Carrero JJ, Gungor O, Demirci MS, Ozbek SS, et al. ssociations of triiodothyronine levels with carotid atherosclerosis and arterial stiffness in hemodialysis patients. Clin J Am Soc Nephrol 2011; 6: 2240-6.

  27. Tatar E, Sezis Demirci M, Kircelli F, Gungor O, Yaprak M, Asci G, Basci A, et al. The ssociation between thyroid hormones and arterial stiffness in peritoneal dialysis patients. Int Urol Nephrol 2012; 44: 601-6.

  28. Feely J, Isles TE. Screening for thyroid dysfunction in diabetics. Br Med J 1979; 1: 678.

  29. Gray RS, Irvine WJ, Clarke BF. Screening for thyroid dysfunction in diabetics. Br Med J 979; 2: 1439.

  30. Chamba A, Neuberger J, Strain A, Hopkins J, Sheppard MC, Franklyn JA. Expression and unction of thyroid hormone receptor variants in normal and chronically diseased human liver. Clin Endocrinol Metab 1996; 81:360-7.

  31. Liangpunsakul S, Chalasani N. Is hypothyroidism a risk factor for non-alcoholic teatohepatitis? J Clin Gastroenterol 2003; 37: 340-3.

  32. Perra A, Simbula G, Simbula M, Pibiri M, Kowalik MA, Sulas P, Cocco MT, et al. Thyroid ormone (T3) and TRbetaagonist GC-1 inhibit/reverse nonalcoholic fatty liver in rats. FASEB J 2008; 22: 2981-9.

  33. Cable EE, Finn PD, Stebbins JW, Hou J, Ito BR, van Poelje PD, Linemeyer DL, et al. eduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist. Hepatol 2009; 49: 407-17.

  34. Akino K, Akita S, Mizuguchi T, Takumi I, Yu R, Wang XY, Rozga J, et al. A novel molecular arker of pituitary tumor transforming gene involves in a rat liver regeneration. J Surg Res 2005; 129: 142-6.

  35. Mollica MP, Lionetti L, Moreno M, Lombardi A, De Lange P, Antonelli A, Lanni A, et al. ,5-diiodo-l-thyronine, by modulating mitochondrial functions, reverses hepatic fat ccumulation in rats fed a high-fat diet. J Hepatol 2009; 51: 363-70.

  36. Naehrlich L, Dörr HG, Bagheri-Behrouzi A, Rauh M. Iodine deficiency and subclinical ypothyroidism are common in cystic fibrosis patients. J Trace Elem Med Biol 2013; 27: 122-5.

  37. Itoh S, Matsuo S, Oda T, Marutani K, Sasaki K. Triiodothyronine level and triiodothyronine/thyroxine ratio in HBeAg-positive chronic hepatitis patients reated with prednisolone withdrawal. Dig Dis Sci 1990; 35: 1110-4.




2020     |     www.medigraphic.com